文献速递肿瘤 PET/CT甲状腺核医学

放射性碘标记小分子酪氨酸激酶抑制剂用于HER2选择性SPECT显像

Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging.
PubMed 文献 · J Nucl Med · 2018-04-13

研究合成并评估了HER2选择性抑制剂CP724,714的放射性碘标记类似物125/131I-IBA-CP,在HER2阳性或阴性人乳腺癌皮下异种移植瘤中进行SPECT显像与生物分布研究。结果显示125I-IBA-CP在HER2阳性肿瘤中摄取显著高于125I-ICP,且可被过量IBA-CP阻断而不被厄洛替尼阻断。结论认为该探针有希望用于HER2阳性肿瘤的体内检测。

要点

  • IBA-CP对HER2的体外抑制活性半数抑制浓度为16 nM,选择性优于其他6种癌症相关酪氨酸激酶。
  • 125/131I-IBA-CP典型放射化学产率约65%(衰变校正),放射化学纯度大于98%,合成结束时摩尔活度为42 GBq/μmol。
  • SPECT显像显示125I-IBA-CP在HER2阳性MDA-MB-453肿瘤中的摄取显著高于125I-ICP,HER2阴性MCF-7肿瘤摄取低得多。

核心结论

  • 放射性标记的HER2选择性抑制剂125/131I-IBA-CP是有希望用于HER2阳性肿瘤体内检测的探针。

研究设计与样本

  • 研究合成CP724,714类似物IBA-CP,并采用铜介导放射性碘化法制备125/131I-IBA-CP,在HER2阳性或阴性人乳腺癌皮下异种移植瘤小鼠中进行体外生物学活性评估、小动物125I-IBA-CP SPECT显像与生物分布研究。

主要发现

  • IBA-CP对HER2的体外抑制活性半数抑制浓度为16 nM,对HER2的选择性优于其他6种癌症相关酪氨酸激酶。
  • 125/131I-IBA-CP典型放射化学产率约65%(衰变校正),放射化学纯度大于98%,合成结束时摩尔活度为42 GBq/μmol。
  • SPECT显像显示125I-IBA-CP在HER2阳性MDA-MB-453肿瘤中的摄取显著高于125I-ICP,HER2阴性MCF-7肿瘤摄取低得多。
  • MDA-MB-453肿瘤中125I-IBA-CP的结合可被共注射过量IBA-CP阻断,但不被厄洛替尼阻断。

关键数值与推荐

  • IBA-CP对HER2的体外抑制活性半数抑制浓度为16 nM。
  • 125/131I-IBA-CP放射化学产率约65%(衰变校正),放射化学纯度大于98%,合成结束时摩尔活度42 GBq/μmol。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One of the most clinically relevant molecular aberrations in breast cancer is overexpression of human epidermal growth factor receptor type 2 (HER2). We aimed to develop a radiolabeled tyrosine kinase inhibitor for HER2-targeted breast cancer imaging. In this study, a radioiodinated analog (125/131I-IBA-CP) of the HER2-selective inhibitor CP724,714 was prepared and evaluated in HER2-positive or -negative subcutaneous human breast cancer xenografts. Methods: The CP724,714 analog IBA-CP was synthesized and assayed for its inhibitory activities against HER2 and 6 other tyrosine kinases. 125/131I-IBA-CP was prepared using a copper-mediated radioiodination method with enhanced labeling yield and molar activity. In vitro biologic activity, including specific and nonspecific binding of 131I-IBA-CP to its HER2 kinase target, was assessed in different cell lines. In vivo small-animal 125I-IBA-CP SPECT imaging and biodistribution studies were conducted on mice bearing HER2-positive, HER2-negative, or epidermal growth factor receptor (EGFR)-positive tumors. Nonradioactive IBA-CP and the EGFR inhibitor erlotinib were used as blocking agents to investigate the binding specificity and selectivity of 125/131I-IBA-CP toward HER2 in vitro and in vivo. Additionally, 125/131I-ICP was prepared by direct radioiodination of CP724,714 for comparison with 125/131I-IBA-CP. Results: IBA-CP displayed superior in vitro inhibitory activity (half-maximal inhibitory concentration, 16 nM) and selectivity for HER2 over 6 other cancer-related tyrosine kinases. 125/131I-IBA-CP was prepared in a typical radiochemical yield of about 65% (decay-corrected), radiochemical purity of more than 98%, and molar activity of 42 GBq/μmol at the end of synthesis. SPECT imaging revealed significantly higher uptake of 125I-IBA-CP than of 125I-ICP in the HER2-positive MDA-MB-453 tumors. Uptake in the HER2-negative MCF-7 tumors was much lower. Binding of 125I-IBA-CP in the MDA-MB-453 tumors was blocked by coinjection with an excess amount of IBA-CP, but not by erlotinib. Conclusion: The radiolabeled HER2-selective inhibitor 125/131I-IBA-CP is a promising probe for in vivo detection of HER2-positive tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tang L, Peng C, Tang B, et al. Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging. J Nucl Med. 2018. PMID: 29653973. doi:10.2967/jnumed.117.205088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。